For instance, Reddy et al. (2016) observed a significant reduction in overall hypoglycaemia (from 17.9% with insulin pump therapy to 3% with the FCLS) but reported an increase in 24-hour and nighttime hyperglycaemia with the FCLS. This evidence concerns the gene INS and Hyperglycemia.